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or position, with no single imaging modality encompassing all 
potential GTV regions. These data suggest delineation based 
upon multimodality imaging has the potential to improve the 
accuracy of GTV definition, which is important for highly 
volumetric approaches to target volume delineation and dose 
escalation strategies.  
   
OC-0064   
Hypercellularity components of glioblastoma identified by 
high b-value DWI: the potential for target definition 
P.P. Pramanik1, H.A. Parmar2, A.G. Mammoser3, L.R. Junck3, 
M.M. Kim1, C.I. Tsien1, T.S. Lawrence1, Y. Cao4 
1University of Michigan, Radiation Oncology, Ann Arbor, USA  
2University of Michigan, Radiology, Ann Arbor, USA  
3University of Michigan, Neurology, Ann Arbor, USA  
4University of Michigan, Radiation Oncology-Radiology-
Biomedical Engineering, Ann Arbor, USA  
 
Purpose/Objective: Conventional MRI for target definition of 
glioblastoma (GB) may receive inadequate radiation dose 
coverage of the nonenhanced (NE) hypercellular (HC) 
subvolume resulting in reduced therapeutic efficacy. It is a 
challenge to differentiate NE solid tumor from edema using 
conventional FLAIR and ADC (b≤1000 s/mm2) images. This 
study aimed to develop a technique to identify the HC 
components of GB by using high b-value diffusion weighted 
imaging (DWI) and to investigate the relationship of these 
components with the enhanced subvolumes, 95% prescribed 
radiation dose volume (95PDV) and progression-free survival 
(PFS). 
Materials and Methods: 21 patients (age: 23-76 years) with 
GB were treated by radiation therapy (RT) after surgical 
resection or biopsy. RT planning was based upon conventional 
MRI. During MRI simulation, DWI was acquired in 3 orthogonal 
directions with b-values of 0, 1000, and 3000 s/mm2. Gross 
tumor volume (GTV-Gd) and FLAIR abnormality volume (FLAIR 
TV) were defined on post-Gadolinium T1-weighted and T2 
FLAIR images pre-RT. High b-value (3000 s/mm2) DWI, in 
which fluid, edema, grey and white matter, to an extent, are 
suppressed, were used to define the HC volume (HCV) by 
using a threshold (mean intensity + 2 SD) calculated from a 
VOI in normal-appearing tissue most contralateral to the 
tumor (Fig 1). All images, including planning CT (dose 
distribution) and MRI at recurrence, were registered to post-
Gd T1WI pre-RT. Relationships between the HCV, GTV-Gd, 
FLAIR TV, 95PDV and PFS were analyzed. 
 
 
 
Results: The HCVs and NE HCVs varied from 0.58 to 67 cc 
(median: 9.8 cc) and 0.15 to 60 cc (median: 2.5 cc), 
respectively. 14 patients had incomplete dose coverage of 
the HCV, of which 6 patients had 1 cc or more HCV missed by 
the 95PDV (range: 1.01-25.4 cc), indicating insufficient 
radiation dose coverage of the HCVs when using conventional 
MRI. In 7 patients, HCVs extended beyond FLAIR TVs an 
average of 13 mm (range: 5-27 mm). However, overall, HCVs 
were only a median 12% of the FLAIR TVs (median volume of 
70 cc and range: 23-180 cc), indicating a potential risk of 
radiation toxicity if FLAIR TV is used to guide high-dose 
treatment. Of the 15 patients who had progression, 5 
patients progressed earlier, within 6 months post-RT, and 10 
patients after. Pre-RT HCVs within the recurrent GTVs-Gd 
were 78% (range: 65-89%) for the earlier progression subgroup 
and 53% (range: 0-85%) for the later progression subgroup, 
indicating the consequence of HCV on PFS. In fact, HCV and 
NE HCV were significant negative prognostic indicators for 
PFS (univariate cox regression, n = 21, p < 0.002 and p < 0.01, 
respectively). The volume of HCV that was not covered by 
the 95PDV was also a significant negative predictor for PFS (p 
< 0.05), substantiating the importance of high dose coverage 
of the HCV.  
Conclusions: High b-value DWI identifies the HC components 
of GB and could aid in RT target volume definition. Future 
pathological studies will allow us to investigate the role of 
high b-value DWI in identifying radiation boost volumes and 
diagnosing progression. 
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Purpose/Objective: Hyperthermia treatment (HT) aims at 
tumour heating to approximately 43°C using RF antennas for 
energy deposition. For accurate Hyperthermia Treatment 
Planning (HTP), the knowledge of patient-specific electrical 
tissue conductivity (σ) values is required. Currently, HTP 
applies literature values for σ, which show large variations 
due to variable measuring conditions (e.g. in vivo, ex vivo, 
temperature) and use of various species. As σ has a strong 
impact on the Specific Absorption Rate (SAR) and 
temperature distribution, studies have shown that 
uncertainties in tissue σ can lead to inaccuracies of 20% in 
both SAR and temperature predictions for HTP. Therefore, 
accurate σ values are essential for reliable patient-specific 
HTP. Moreover, tumor σ is unknown; therefore currently σ 
values of muscle are applied. Our aim is to acquire patient-
specific tissue σ non-invasively using MRI. 
Materials and Methods: In vivo σ reconstructions were 
performed using the Electric Property Tomography (EPT) 
method which reconstructs the tissue σ from the B1+ fields, as 
measurable by standard MRI systems. We have validated this 
method earlier using phantom experiments and in vivo 
simulations in the pelvic region. In the present study, in vivo 
3T MRI measurements of 12 cervical (squamous cell) 
carcinoma patients and one uterine adenocarcinoma patient 
were used to reconstruct σ values in tumor, muscle and 
bladder. For a reliable σ reconstruction using EPT, the size of 
a particular tissue type should be relatively homogenous and 
large enough (>3cm), therefore, the σ of 9 tumors and 7 
bladder fillings could be reliably reconstructed. Results were 
compared to literature data. 
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Results: 
 
In figure 1 the reconstructed and literature σ values of 
muscle, bladder and cervical tumor tissue are presented. 
Results show σ values of muscle tissue which are 15-30% 
elevated compared to literature values. Moreover, the 
reconstructed σ values of the bladder were up to 10 times 
higher than values currently used in HTP. Furthermore, for 
75% of the squamous cell carcinomas the σ values were 5-12% 
higher than the σ of muscle tissue. The reconstructed σ of 
the adenocarcinoma was 22% higher compared to muscle 
tissue. 
Conclusions: This study demonstrated the feasibility to 
quantitatively measure the σ of healthy tissue and tumors in 
vivo. The measured conductivities were higher than those 
reported in literature, which could probably be explained by 
the higher blood and water content during living conditions. 
A decrease of σ after death has been reported in literature in 
studies with (human) liver, (animal) brain and (animal) 
muscle tissue. The present study showed that the commonly 
unknown tumor σ is 5-12% higher compared to the in vivo σ of 
muscle. The reconstructed bladder σ was much higher than 
the value currently used in HTP. This can be explained by the 
fact that the σ value reported in the literature corresponds 
to the bladder tissue, not accounting for the highly 
conductive urine. Future studies will determine to which 
extent the reliability of HTP improves when using these 
patient-specific σ values.  
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Purpose/Objective: To evaluate the feasibility of prostate 
cancer EBRT response assessment with [11C]Acetate PET and 
multiparametric magnetic resonance imaging (mpMRI) in the 
absence of a hybrid MR-PET scanner. The study aimed at 
finding the correlation of quantitative parameters changes 
derived from different imaging modalities during the course 
of treatment. 
Materials and Methods: Four cases with biopsy-confirmed 
prostate cancer were included in this IRB approved study. 
Patients received a prescribed dose of 78Gy to the prostate 
and 50.4Gy to elective pelvic nodes. PET-CT and mpMRI scans 
were performed at 4 time points: before RT, after 2 and 4 
weeks of treatment (at ~20 and 40 Gy) and at 3 months after 
RT. For the PET exam 740MBq of [11C]Acetate were injected 
and patients were imaged 20 minutes later. 3T mpMRI scan 
consisted of the following sequences: T2-weighted turbo spin 
echo, diffusion-weighted single-shot echo-planar imaging 
(DWI), 3D Chemical Shift Imaging spectroscopy (CSI) and 
dynamic contrast enhanced (DCE) T1-weighted gradient echo 
with 70 repetitions. ADC, Ktrans, iAUC and Cho+Cr/Ci-ratio 
maps were generated using the Syngo® (Siemens, Germany). 
All images were registered and analzyed in the Mirada RTx 
(Mirada Medical Ltd, UK) using automatic and manual rigid 
registration with respect to three reference gold markers. 
Series of structures (defined on datasets from all consecutive 
time points) consisted of: focal lesion visible on particular 
modality (T2w; ADC-, Ktrans-, iAUC-maps and PET), reference 
PET structure (Gluteus maximus m.) to calculate TBR and the 
dominant intraprostatic lesion (DIL) based on all imaging 
modalities. DIL defined at the baseline was also copied to 
remaining time points (DILB2-4) to assess temporal stability of 
the DIL. Variations in quantitative parameters were extracted 
from the respective imaging series. Statistical analyses were 
performed on collected data. 
Results: Manually delineated DIL mean volume at the 
baseline was 3.1±1.6cc and decreased to 0.25±0.25cc at 
follow up (with 23.0±3.8% and 44.3±28.5% decrease after 2 
and 4 weeks, respectively). Means of quantitative parameters 
in the DIL volumes between baseline and follow up changed 
as follows: ADC increased by 27.1±7.4%, Ktrans decreased by 
41.5±11.4% and iAUC by 34.8±12.2%. Intensity on T2w images 
decreased by 5.2±7.9% and TBR dropped by 25.1±6.5%. The 
behavior of these parameters during treatment differed 
between cases. For example for one patient the lesion was 
not visible on T2w images already after 20Gy, whereas for 
another one it could be recognized even in follow up after 
78Gy. 
Conclusions: Prostate cancer RT assessment is feasible with 
combined [11C]Acetate PET and mpMRI performed on separate 
scanners. Special care has to be devoted to the process of 
image registration. Data derived from different modalities 
complement each other but their correlations need further 
investigations. There is clear inter-patient response variation 
but more patients and long term follow up is needed. The 
impact of temporal DIL variations on boost strategies needs 
further investigation.  
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Purpose/Objective: Neoadjuvant chemoradiotherapy (nCRT) 
is often used for the treatment of resectable esophageal 
cancer. In 29% of the patients complete pathologic response 
(pCr) has been found. When accurate prediction of treatment 
response is available, surgery may potentially be omitted in 
case of pCr. Changes in tumor microvasculature are reflected 
in dynamic contrast enhanced (DCE) MRI, which is therefore 
